Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Paroxysmal Nocturnal Hemoglobinuria Treatment Market: By Treatment Type, By Drug Type, By Distribution Channel, and Region Forecast 2020-2031
Paroxysmal Nocturnal Hemoglobinuria Treatment Market size was valued at US$ 6.4 billion in 2022 and is projected to reach US$ 12.3 billion by 2029, growing at a 6.2% CAGR from 2023 to 2029. Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder that leads to the premature death and impaired production of blood cells, it presents clinically with a variety of symptoms, the most prevalent of which are hemolytic anemia, hemoglobinuria, and somatic symptoms including fatigue and shortness of breath, increase in the prevalence of blood disorder globally consequences rise in PNH treatment market growth, According to National Organization of Rare Diseases, The prevalence is estimated to be between 0.5-1.5 per million people in the general population, affects males and females in equal numbers, although some studies show a slightly more female affected.
The industry is influenced by continuous technological development in healthcare infrastructure along with research and development to improve specific therapies which leads to the major factor that drives the market growth. With the rising prevalence of hemoglobinuria globally the key players focusing on research and development activities and undergoing clinical trials for the treatment, in addition, the numerous approaches for the development of anti-C5 monoclonal antibodies influence the revenue growth leads to create lucrative opportunities. To treat patients with repeated hemolysis and anemia, blood transfusion, and iron supplements were administered to cause adverse reactions, also the unavailability of specialty professionals limits the market growth, high cost of treatment hampers the emerging economics countries’ market resist the growth.
Study Period
2025-2031Base Year
2024CAGR
6.2%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The increasing prevalence of blood disorders across the world is the major market driver in the Paroxysmal Nocturnal Hemoglobinuria Treatment market during the forecast period. Increasing incidences of hematological disorders across the globe such as anemia, bleeding disorders such as hemophilia, blood clots, and blood cancers such as leukemia, lymphoma, and myeloma seen common in the present era, demand efficient treatment and influence the market growth. The technological advancement and undergoing clinical trials drugs are offers specific therapies contributing to market development along with government initiatives for better treatment facilities drive the market growth at a significant rate.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2022 |
US$ 6.4 billion |
Market Size in 2029 |
US$ 12.3 billion |
Market CAGR |
6.2% |
By Treatment |
|
By Drug Type |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The paroxysmal nocturnal hemoglobinuria treatment market size was valued at US$ 6.4 billion in 2022 and is projected to reach US$ 12.3 billion by 2029, growing at a 6.2% CAGR from 2023 to 2029.
The leading players in the Paroxysmal Nocturnal Hemoglobinuria Treatment market are Novartis AG, Apellis Pharmaceuticals, AbbVie, Allergan, Novartis AG, Johnson & Johnson, Bayer AG, Takeda Pharmaceuticals, Bristol-Myers Squibb Company, Mylan N.V., Amgen Inc., Alexion Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Amgen Inc., GE Healthcare, Ra Pharmaceuticals, Regeneron Pharmaceuticals, Inc., and Thermo Fisher Scientific Inc.
Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation, and Seven years forecast is presented from 2023 – 2029.
1.Executive Summary |
2.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Introduction |
2.1.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Taxonomy |
2.2.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Definitions |
2.2.1.Treatment |
2.2.2.Drug Type |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Stem Cell Transplant |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Blood Transfusion |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Anti C5 monoclonal antibodies |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Danicopan |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Iron supplements |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. others |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Retail Pharmacy |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Hospital Pharmacy |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacy |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Stem Cell Transplant |
9.1.2.Blood Transfusion |
9.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Anti C5 monoclonal antibodies |
9.2.2.Danicopan |
9.2.3.Iron supplements |
9.2.4.others |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Retail Pharmacy |
9.3.2.Hospital Pharmacy |
9.3.3.Online Pharmacy |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Stem Cell Transplant |
10.1.2.Blood Transfusion |
10.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Anti C5 monoclonal antibodies |
10.2.2.Danicopan |
10.2.3.Iron supplements |
10.2.4.others |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Retail Pharmacy |
10.3.2.Hospital Pharmacy |
10.3.3.Online Pharmacy |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
10.4.7. |
11.Asia Pacific (APAC) Paroxysmal Nocturnal Hemoglobinuria Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Stem Cell Transplant |
11.1.2.Blood Transfusion |
11.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Anti C5 monoclonal antibodies |
11.2.2.Danicopan |
11.2.3.Iron supplements |
11.2.4.others |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Retail Pharmacy |
11.3.2.Hospital Pharmacy |
11.3.3.Online Pharmacy |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Paroxysmal Nocturnal Hemoglobinuria Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Stem Cell Transplant |
12.1.2.Blood Transfusion |
12.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Anti C5 monoclonal antibodies |
12.2.2.Danicopan |
12.2.3.Iron supplements |
12.2.4.others |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Retail Pharmacy |
12.3.2.Hospital Pharmacy |
12.3.3.Online Pharmacy |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Stem Cell Transplant |
13.1.2.Blood Transfusion |
13.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Anti C5 monoclonal antibodies |
13.2.2.Danicopan |
13.2.3.Iron supplements |
13.2.4.others |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Retail Pharmacy |
13.3.2.Hospital Pharmacy |
13.3.3.Online Pharmacy |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Novartis AG |
14.2.2.Apellis Pharmaceuticals |
14.2.3.AbbVie |
14.2.4.Allergan |
14.2.5.Novartis AG |
14.2.6.Johnson & Johnson |
14.2.7.Bayer AG |
14.2.8.Takeda pharmaceuticals |
14.2.9.Bristol-Myers Squibb Company |
14.2.10.Mylan N.V. |
14.2.11.Amgen Inc. |
14.2.12.Alexion Pharmaceuticals |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players